Development plans for ABN501∙202 also revealed
[by Ji, Yong Jun] Abion announced on March 19 that it will present two studies — “Nonclinical Results of 토토 카지노 (ABN401) in Combination with Lazertinib” and “Development Strategies for ABN501 and ABN202” — at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in Chicago, Illinois, from April 25 to 30.
The company previously reported strong anti-tumor activity in a patient-derived xenograft (PDX) model harboring EGFR mutations, with a 96.6% tumor growth inhibition (TGI) rate with the combination treatment. This results suggest that the combination could be an effective cancer treatment strategy, according to the company. At AACR, the company will present the latest findings from the combination, a drug-drug interaction (DDI) study of 토토 카지노 and lazertinib.
The combination of the two drugs showed a low potential for interaction, with neither drug affecting the efficacy of the other. These findings suggest that 토토 카지노 can be safely used in combination with lazertinib to maximize therapeutic efficacy without drug interference.
The combination of 토토 카지노 and lazertinib may offer new hope for lung cancer patients with hepatocyte growth factor receptor (MET) amplification and epidermal growth factor receptor (EGFR) mutations," said Company officials. "Now that we have received approval from both the U.S. Food and Drug Administration (FDA) and Korea’s Ministry of Food and Drug Safety (MFDS) to amend the protocol for the phase 2 trial, we look forward to rapidly advancing the study to provide more effective and innovative treatment options."
토토 카지노 will also present its development strategy for ABN501 and ABN202. ABN501, an antibody therapy targeting claudin 3 (CLDN3), has demonstrated its high safety profile in both monkey and rat models and effective anti-cancer activity in non-clinical models. BsABN501 (anti-CLDN3xCD3 T cell engager), a bispecific T cell engager targeting both CLDN3 and CD3, is designed to activate T cells and eliminate CLDN3-expressing cancer cells. In preclinical studies, BsABN501 induced strong cytotoxic effects and significantly reduced tumor size in animal models.
The company will also present results from nonclinical studies of its antibody-cytokine conjugate platform ABN202 targeting TROP2. In particular, the company aims to demonstrate its strategy to develop 'Beyond ADCs' that overcome the limitations of conventional ADCs. The platform demonstrated superior efficacy compared to traditional ADCs in models of ADC resistance and low antigen expression.